New Delhi: The US Food and Drug Administration (USFDA) has concluded an onsite inspection of the pharmacovigilance and post-marketing surveillance system at Zydus Lifesciences' office in New Jersey, USA, with nil observations, the company said in a regulatory disclosure.

According to the company, the USFDA conducted the inspection from September 22 to September 25, 2026, covering its pharmacovigilance and post-marketing surveillance system.

The inspection concluded with nil observations, Zydus said.

Also Read: Zydus Lifesciences' US Arm Agrees to Pay USD 5.9 Mn to Settle Generic Drug Pricing Litigation

Zydus Lifesciences is a global life-sciences company involved in discovering, developing, manufacturing and marketing healthcare therapies. According to its official website, the Zydus Group has manufacturing sites and research facilities across India as well as in the US and Brazil, with a presence in regulated markets including the US and Europe and in several emerging markets. The group’s areas of research include cardio-metabolic diseases, inflammation and immunology, neurosciences, oncology and rare diseases, along with biologics, vaccines and other healthcare products.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .